Publication:
Analysis of pediatric thrombotic patients in Turkey

dc.contributor.authorDevecioǧlu, Ömer
dc.contributor.authorErtem, M.
dc.contributor.authorVergin, Canan
dc.contributor.authorKavaklı, Kaan
dc.contributor.authorCanatan, D.
dc.contributor.authorToksoy, Hayri
dc.contributor.authorYıldız, İnci
dc.contributor.authorKürekçi, Emin
dc.contributor.authorÖzgen, Ünsal
dc.contributor.authorÖniz, Haldun
dc.contributor.authorGürgey, Aytemiz
dc.contributor.authorÖren, Hale
dc.contributor.buuauthorMeral, Adalet
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentÇocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.contributor.scopusid6602571317
dc.date.accessioned2022-03-30T10:35:05Z
dc.date.available2022-03-30T10:35:05Z
dc.date.issued2004
dc.description.abstractThis study analyzes the data of thrombotic children who were followed up in different pediatric referral centers of Turkey, to obtain more general data on the diagnosis, risk factors, management, and outcome of thrombosis in Turkish children. A simple two-page questionnaire was distributed among contact people from each center to standardize data collection. Thirteen pediatric referral centers responded to the invitation and the total number of cases was 271. All children were diagnosed with thromboembolic disease between January 1995 and October 2001. Median age at time of first thrombotic event was 7.0 years. Of the children 4% of the cases were neonates, 12% were infants less than 1 year old, and 17% were adolescents. Thromboembolic event was mostly located in the cerebral vascular system (32%), deep venous system of the limbs, femoral and iliac veins (24%), portal veins (10%), and intracardiac region (9%). Acquired risk factors were present in 86% of the children. Infection was the most common underlying risk factor. Inherited risk factors were present in 30% of the children. FVL was the most common inherited risk factor. Acquired and inherited risk factors were present simultaneously in 19% of the patients. Eleven children had a history of familial thrombosis. Due to the local treatment preferences, the treatment of the children varied greatly. Outcome of the 142 patients (52%) was reported: 88 (62%) patients had complete resolution, 47 (33%) had complications, 12 (9%) had recurrent thrombosis, and 34 (24%) died. Three children (2.1%) died as a direct consequence of their thromboembolic disease. The significant morbidity and mortality found in this study supports the need for multicentric prospective clinical trials to obtain more generalizable data on management and outcome of thrombosis in Turkish children.
dc.identifier.citationÖren, H. vd. (2004). “Analysis of pediatric thrombotic patients in Turkey”. Pediatric Hematology and Oncology, 21(7), 573-583.
dc.identifier.endpage583
dc.identifier.issn0888-0018
dc.identifier.issue7
dc.identifier.pubmed15626013
dc.identifier.scopus2-s2.0-5044234800
dc.identifier.startpage573
dc.identifier.urihttps://doi.org/10.1080/08880010490500935
dc.identifier.urihttps://www.tandfonline.com/doi/full/10.1080/08880010490500935
dc.identifier.urihttp://hdl.handle.net/11452/25444
dc.identifier.volume21
dc.identifier.wos000223843200001
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherTaylor & Francis
dc.relation.collaborationYurt içi
dc.relation.journalPediatric Hematology and Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectOncology
dc.subjectHematology
dc.subjectPediatrics
dc.subjectChildhood
dc.subjectThromboembolism
dc.subjectThrombosis
dc.subjectVenous thromboembolic complications
dc.subjectMolecular-weight heparin
dc.subjectV-leiden mutation
dc.subjectRisk-factors
dc.subjectChildren
dc.subjectDisease
dc.subjectThrombophilia
dc.subjectHemostasis
dc.subjectDiagnosis
dc.subjectTherapy
dc.subject.emtreeAntithrombin III
dc.subject.emtreeBlood clotting factor 5 Leiden
dc.subject.emtreeHeparin
dc.subject.emtreeLow molecular weight heparin
dc.subject.emtreeProtein C
dc.subject.emtreeProtein S
dc.subject.emtreeStreptokinase
dc.subject.emtreeTissue plasminogen activator
dc.subject.emtreeUrokinase
dc.subject.emtreeWarfarin
dc.subject.emtreeAdolescent
dc.subject.emtreeArteriovenous fistula
dc.subject.emtreeArticle
dc.subject.emtreeAtaxia
dc.subject.emtreeAtrophy
dc.subject.emtreeBrain blood vessel
dc.subject.emtreeChild
dc.subject.emtreeDeep vein thrombosis
dc.subject.emtreeEpilepsy
dc.subject.emtreeFemoral artery
dc.subject.emtreeFemoral vein
dc.subject.emtreeFollow up
dc.subject.emtreeFulminating purpura
dc.subject.emtreeHepatic artery
dc.subject.emtreeHuman
dc.subject.emtreeIliac artery
dc.subject.emtreeIliac vein
dc.subject.emtreeInfant
dc.subject.emtreeInfection
dc.subject.emtreeInformation processing
dc.subject.emtreeIntracardiac thrombosis
dc.subject.emtreeKidney atrophy
dc.subject.emtreeKidney vein thrombosis
dc.subject.emtreeLimb amputation
dc.subject.emtreeLimb injury
dc.subject.emtreeLiver dysfunction
dc.subject.emtreeLiver vein thrombosis
dc.subject.emtreeLung disease
dc.subject.emtreeLung embolism
dc.subject.emtreeMajor clinical study
dc.subject.emtreeMesenteric vein thrombosis
dc.subject.emtreeMortality
dc.subject.emtreeMotor dysfunction
dc.subject.emtreeNewborn
dc.subject.emtreeOcclusive cerebrovascular disease
dc.subject.emtreePortal hypertension
dc.subject.emtreePortal vein thrombosis
dc.subject.emtreeQuestionnaire
dc.subject.emtreeRecurrent disease
dc.subject.emtreeRetina artery
dc.subject.emtreeRisk factor
dc.subject.emtreeSplenic vein
dc.subject.emtreeThromboembolism
dc.subject.emtreeThrombosis
dc.subject.emtreeTime
dc.subject.emtreeTreatment outcome
dc.subject.emtreeTremor
dc.subject.emtreeTurkey (Republic)
dc.subject.emtreeVenule
dc.subject.emtreeVisual impairment
dc.subject.meshChild
dc.subject.meshHumans
dc.subject.meshMutation
dc.subject.meshThromboembolism
dc.subject.meshThrombosis
dc.subject.meshTurkey
dc.subject.scopusVenous Thromboembolism; Pediatrics; Thrombosis
dc.subject.wosOncology
dc.subject.wosHematology
dc.subject.wosPediatrics
dc.titleAnalysis of pediatric thrombotic patients in Turkey
dc.typeArticle
dc.wos.quartileQ4
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
local.indexed.atScopus
local.indexed.atWOS

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: